Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Using the Cutting Edge Tech, Georgetown team proves the purpose of pancreatic canceron January 20, 2021 at 5:31 am
Using the Cutting Edge Tech, Georgetown team proves the purpose of pancreatic cancer “If you look at science, you don't ask whether ...
- NEUVOGEN Announces Next Generation Cancer Vaccine Strategy to Transform how Solid Tumors are Treatedon January 20, 2021 at 4:42 am
NEUVOGEN, an immunoncology company, announces its novel cancer vaccine strategy to transform how solid tumors are treated. NEUVOGEN's stra ...
- US Breast Cancer Drug Antibodies Immunotherapy Therapeutics Market Offers USD 20 Billion Opportunity by 2026on January 20, 2021 at 2:59 am
DELHI, India, (GLOBE NEWSWIRE) -- "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: US breast cancer market has experienced advancements in the ...
- The Denvax Clinic Offering Dendritic Cell Therapy for the Effective Treatment of Canceron January 19, 2021 at 9:05 pm
The Denvax Clinic is helping the cancer patients by way of its Denvax treatment, which is the customised dendritic cell-based cancer immunotherapy given to fight against cancer cells. This press ...
- Immunotherapy biotech NexImmune files for an $86 million IPOon January 19, 2021 at 1:42 pm
N exImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. NexImmune is developing a novel ...
- Study predicts good passive immunotherapy donors to combat COVID-19on January 19, 2021 at 10:09 am
A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.
- Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMBon January 19, 2021 at 8:55 am
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low.
- Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapyon January 19, 2021 at 8:31 am
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs™ cellular immunotherapy. In a series ...
- New immunotherapy cancer treatment given the green light on the NHSon January 19, 2021 at 12:03 am
Around 100 patients a year in England will be among the first in the world to get cutting-edge cancer treatment on the NHS after regulators approved the use of a new immunotherapy treatment. The (NICE ...
- Study may help develop more effective personalized immunotherapy for cancer patientson January 14, 2021 at 10:01 pm
New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective ...
via Bing News